Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
A phase 3 trial of Revumenib in acute myeloid leukaemia, run by Syndax Pharmaceuticals, now recruiting.
Overview
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation is a phase 3 interventional study registered as NCT07211958 by Syndax Pharmaceuticals, with 468 participants planned, started 2025-11-25 and due to reach its primary completion in 2029-06. Interventions recorded: Revumenib, Placebo and Intensive Chemotherapy Regimen.
Similar pages
not linked directly; found by shared links- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPhase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Shares Acute myeloid leukaemia and the tag pipeline.